HALOZYME THERAPEUTICS, INC. Debt Securities Available For Sale Excluding Accrued Interest Current
HALOZYME THERAPEUTICS, INC. (HALO) had Debt Securities Available For Sale Excluding Accrued Interest Current of $67.86 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent · last filed 2026-08-06
- 2026-06-30: Debt Securities Available For Sale Excluding Accrued Interest Current $67.86M.
- 2026-03-31: Debt Securities Available For Sale Excluding Accrued Interest Current $8.87M.
- 2025-12-31: Debt Securities Available For Sale Excluding Accrued Interest Current $9.00M.
- 2025-09-30: Debt Securities Available For Sale Excluding Accrued Interest Current $282.30M.
| Period end | Debt Securities Available For Sale Excluding Accrued Interest Current |
|---|---|
| 2026-06-30 | $67.86M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $8.87M 10-Q · filed 2026-05-11 |
| 2025-12-31 | $9.00M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $282.30M 10-Q · filed 2025-11-03 |
| 2025-06-30 | $486.32M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $571.59M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $480.22M 10-K · filed 2026-02-17 |
| 2024-09-30 | $511.99M 10-Q · filed 2024-10-31 |
| 2024-06-30 | $341.17M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $298.82M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $217.63M 10-K · filed 2025-02-18 |
| 2023-09-30 | $209.06M 10-Q · filed 2023-11-06 |
| 2023-06-30 | $127.11M 10-Q · filed 2023-08-08 |
| 2022-12-31 | $128.60M 10-K · filed 2024-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |